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Abstract We used mass spectrometry-based protein identi-
fication to determine the presence of granins and other pro-
teins in the mouse neuroblastoma secretome. We detected
polypeptides derived from four members of the granin fam-
ily: chromogranin A, chromogranin B, secretogranin III, and
VGF. Many of them are derived from previously described
biologically active regions; however, for VGF and CgB, we
detected peptides not related to known bioactivities. Along
with granins, we identified 115 other proteins secreted by
mouse neuroblastoma cells, belonging to different function-
al categories. Fifty-six out of 119 detected proteins possess
the signal fragments required for translocation into endo-
plasmic reticulum. Sequences of remaining 63 proteins were
analyzed using SecretomeP algorithm to determine proba-
bility of nonclassical secretion. Identified proteins are in-
volved in the regulation of cell cycle, proliferation,
apoptosis, angiogenesis, proteolysis, and cell adhesion.
Keywords Granins . Neuroblastoma . Secretome .
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Introduction
Over the last few years, there has been a growing interest in
the study of cancer secretome comprising all the proteins
that can be identified in the intestinal fluid of the tumor mass
in vivo which play a key role in the signaling, communica-
tion, and migration of cells [24, 33]. The term of
“secretome” was introduced by Tjalsma in genome-based
studies of Bacillus subtilis proteins [51]. Currently, the
secretome studies include the proteins secreted via classical
and nonclassical pathways but also shed from the surface of
living cells [33]. The cell culture secretome can also be a
suitable tool for investigating proteins released in vivo by
tumors and used to identify putative tumor markers [9].
Neuroblastoma is the most common extracranial solid tumor
of the sympathetic nervous system occurring in childhood.
This neuroendocrine tumor secretes a range of proteins,
which could serve as the potential biomarkers for diagnosis
and monitoring of the treatment or disease progression [11,
46]. Several serum prognostic factors, such as neuron spe-
cific enolase, ferritin, and chromogranin A (CgA) have been
used to predict neuroblastoma progression. CgA is currently
the best available biomarker for the diagnosis of neuroen-
docrine tumors [17, 22, 55]. The granin family comprises
nine members including CgA and CgB, secretogranin (Sg)
II, III, IV (HISL-19), V (7B2), VI (NESP55), VII (VGF),
and proSAAS [15, 16, 18, 56]. Potential utility of CgB,
SgII, and VGF nerve growth factor-inducible protein
(VGF) as biomarkers of neurological and psychiatric disor-
ders has been described [6]. The expression patterns of
granin-derived peptides seem to play an important role in
differentiating between some benign and malignant neuro-
endocrine tumor types [39]. Granins are the main soluble
proteins found in many neuroendocrine cells and in some
neurons. They are present in large dense-core secretory
vesicles and secreted during regulated exocytosis. Granins
regulate the storage of catecholamines and ATP, exhibit pH-
buffering capacities and thus they help to concentrate solu-
ble products for secretion [7, 18, 32]. Their sequences
contain pairs of basic amino acids and monobasic residues
that are the potential cleavage sites for proteases. The
granin-derived peptides fulfill autocrine and paracrine hor-
monal activities. Their relative abundance, functional sig-
nificance, and secretion into the CSF or saliva and the
general circulation made granin peptides tractable targets
as biomarkers for many diseases of neuronal and endocrine
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origin [6]. We used mass spectrometry-based protein iden-
tification to determine the presence of the granin and other
protein-derived peptides in the neuroblastoma secretome.
This approach could deliver new information regarding




The mouse neuroblastoma cell line NEURO-2A was cul-
tured in Eagle’s medium with 10 % fetal bovine serum. One-
day-old cultures were washed twice with PBS and the
serum-free medium was applied. After 24 h culture, media
were collected and centrifuged at 3,000×g for 30 min.
The supernatants were concentrated on centrifugal filters
with the molecular weight cutoff of 3 kDa (Millipore,
UFC900324). Proteins were precipitated using 5 volumes
of cold acetone (−20 °C) and samples were centrifuged at
12,000×g for 10 min at 4 °C. Subsequently, pellets were
resuspended in 8 M urea and diluted with 25 mM ammoni-
um bicarbonate. Proteins were reduced with 10 mM DTT
for 30 min at 57 °C and alkylated with 50 mM
iodoacetamide for 45 min at room temperature (RT) in a
dark. Then samples were treated with 50 mM DTT for
45 min at RT. Seventy micrograms of protein was used for
tryptic digestion and protein identification. Solubilized pro-
teins were digested overnight with sequencing grade modi-
fied trypsin (Promega, V5111, 0.01 μg per 1 μg of protein)
and the reaction was quenched by adding 0.01 %
trifluoroacetic acid.
Mass spectrometry and data analysis
Digested peptides were applied to a RP-18 trapping column
(nanoACQUITY UPLC Symmetry C18 Trap, Waters) using
0.1 % trifluoroacetic acid mobile phase, and then transferred
on to a HPLC RP-18 column (nanoACQUITY UPLC BEH
C18 Column, Waters) using an acetonitrile gradient (0–30 %
in 0.1 % formic acid) for 150 min at a flow rate of
200 nL/min. The column outlet was directly coupled to the
ion source of the Ion Cyclotron Resonance spectrometer
(LTQ61 FTICR, Thermo Electron). For protein identifica-
tion, a series of three LC/MS runs were carried out on each
sample, with the spectrometer running in data-dependent
MS-to-MS/MS switch mode. Each run covered one of sec-
tors of m/z values: 300–600, 500–800, 700–2000.
The parent and product ions lists for the database search
were prepared by merging acquired raw files with Mascot
Distiller software followed by Mascot Search Engine (Ma-
trix Science, London, UK) against the NCBInr and IPI-
Mouse database. Search parameters for precursor and prod-
uct ions mass tolerance were 30 ppm and 0.8 Da, respec-
tively. The other search parameters were as follows: enzyme
specificity was set up to trypsin cleavage and variable mod-
ification of cysteine carbamidomethylation and methionine
oxidation. Peptides with Mascot score exceeding the thresh-
old value corresponding to <5 % false positive rate, calcu-
lated by Mascot procedure, were considered to be positively
identified. At least two peptides per protein with score
above the threshold were required for identification.
The whole experiment was performed twice, using
two biological replicates. Functional categorization of pro-
teins was performed using Protein Analysis Through Evo-
lutionary Relationship system (PANTHER, http://
www.pantherdb.org/) [36] and Gene Ontology (GO) classi-
fication [3]. We determined the presence of the signal pep-
tides and the probability of non classical secretion using the
UniProt database [2] and the SecretomeP algorithm [8],
respectively.
Electrophoresis and western blotting
Electrophoresis and western blotting was done as it was
described previously [29]. Twenty micrograms of proteins
per line was used. The monoclonal antibodies for CgA (Chr-
A E-5), CgB (Chr-B N-20), SgIII (Sg III C-2), and VGF (H-
65) (Santa Cruz Biotechnology, INC) were used according
to manufacturer recommendations.
Results
Our mass spectrometry analysis resulted in the identification
of four members of the granin family in the pool of proteins
secreted by mouse neuroblastoma cells: chromogranin A,
chromogranin B, secretogranin III, and VGF nerve growth
factor-inducible protein. The peptide sequences and identi-
fication parameters are presented in Table 1.
Chromogranin A was identified by detection of seven
polypeptides (18 % sequence coverage). Five of them were
homologous to the fragments of known biologically active
peptides. One peptide (K.ELQDLALQGAK.E) was located
within beta-granin/ vasostatin II region; two others
(K.TEASEALPSEGK.G and K.DDGQSDSQAVDGD
GK.T) were located in pancreastatin region of mouse
chromogranin A. Another two polypeptides (K.VAHQ
LQALR.R and R.AEDQELESLSAIEAELEK.V) were
found in serpinin region. Positions of peptides identified
within the protein sequence of chromogranin A are shown
in Fig. 1.
We identified eight peptides of chromogranin B with
sequence coverage of 16 %. Most of peptides detected for
chromogranin B were localized within N-terminal and in the
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middle part of the protein. Two of them (R.DHNEE
MVTR.C and R.LLDEGHYPVR.E) were located in CgB1-41
and GAWK regions.
We detected six different peptides of secretogranin III
(sequence coverage 18 %). Three of them were related to
chromogranin A-binding domain (K.EANNYEETLD
KPTSR.T, K.VTPVAAVQDGFTNR.E and K.YGTISPEE
GVSYLENLDETIALQTK.N), two were mapped within
the cholesterol-binding domain (R.SPPFDNQLN
VEDADSTK.N and R.SPPFDNQLNVEDADSTK.N), and
one within the carboxypeptidase E (CPE)-binding domain
(R.DFINQQADAYVEK.G). For VGF, we detected seven
peptides (13 % sequence coverage) including fragments
homologous to NERP1-1 (R.LLQQGLAQVEAGR.R) and
TLQP-62 (R.HHPDLEAQAR.R). We confirmed the pres-
ence of particular granins in neuroblastoma secretome using
western blot. Proteins were detected with monoclonal anti-
bodies at the level about 50–70 kDa for secretogranin III,
about 70 kDa for chromogranin B and VGF, and 70–80 kDa
for chromogranin A (Fig. 2).














Chromogranin A 346 18.1 1,034.5865 1,034.5985 453–461 49.74 K.VAHQLQALR.R
gi|6680932 1,044.434 1,044.436 374–382 44.82 R.LEGEDDPDR.S
1,184.6366 1,184.6401 78–88 36.95 K.ELQDLALQGAK.E
1,217.5751 1,217.5775 291–302 44.05 K.TEASEALPSEGK.G
1,334.504 1,334.5109 339–348 51.15 K.QEEEEEEEER.L
1,492.5831 1,492.5914 276–290 90.83 K.DDGQSDSQAVDGDGK.T
2,003.0008 2,002.9582 435–452 88.97 R.AEDQELESLSAIEAELEK.V
Chromogranin B 379 16.2 1,114.4636 1,114.4527 399–407 58.32 R.HGEETEEER.S
gi|6680934 1,129.4734 1,129.4822 27–35 36.48 R.DHNEEMVTR.C
1,197.6101 1,197.6142 438–447 28.67 R.LLDEGHYPVR.E
1,258.5523 1,258.5499 216–226 42.91 R.ADAHSMELEEK.T
1,274.5439 1,274.5448 216–226 50.74 R.ADAHSMELEEK.T (Ox. M)
1,389.6124 1,389.616 300–311 115.4 K.SSYEGHPLSEER.R
1,468.6466 1,468.6542 386–398 42.24 R.NHPDSELESTANR.H
1,510.6417 1,510.6059 341–353 48.53 R.ASEEEPEYGEESR.S
1,530.6815 1,530.6798 102–116 60.17 R.EDAGAPVEDSQGQTK.V
1,986.9232 1,986.9243 131–148 40.13 R.EGVDDQESLRPSNQQASK.E
Secretogranin III
isoform 1
497 23.1 1,473.7428 1,473.7576 233–246 76.77 K.VTPVAAVQDGFTNR.E
gi|6677867 1,539.6937 1,539.7205 441–453 74.49 R.DFINQQADAYVEK.G
1,765.802 1,765.8118 207–221 40.88 K.EANNYEETLDKPTSR.T
1,875.9026 1,875.8486 99–115 110.3 R.SPPFDNQLNVEDADSTK.N
2,734.49 2,734.4388 178–202 143.1 K.LLNLGLITESQAHTLEDEVAEALQK.L
2,769.4311 2,769.3596 319–343 95.21 K.YGTISPEEGVSYLENLDETIALQTK.N
VGF nerve growth
factor
469 13.1 1,009.4654 1,009.4577 423–431 43.85 R.SQEEAPGHR.R
gi|86476054 1,113.5868 1,113.5931 509–519 33.93 R.SPQPPPPAPAR.D
1,159.548 1,159.5469 353–361 45.38 R.ELQETQQER.E
1,169.6189 1,169.6193 489–499 36.03 K.NAPPEPVPPPR.A
1,172.5629 1,172.5686 577–586 40.39 R.HHPDLEAQAR.R
1,381.7696 1,381.7677 299–311 44.82 R.LLQQGLAQVEAGR.R
2,034.0237 2,034.0521 466–483 83.11 K.LHLPADDVVSIIEEVEEK.R
1   MRSTAVLALL LCAGQVFALP VNSPMTKGDT KVMKCVLEVI SDSLSKPSPM 
51  PVSPECLETL QGDERILSIL RHQNLLKELQ DLALQGAKER AQQPLKQQQP 
101 PKQQQQQQQQ QQQEQQHSSF EDELSEVFEN QSPDAKHRDA AAEVPSRDTM 
151 EKRKDSDKGQ QDGFEATTEG PRPQAFPEPN QESPMMGDSE SPGEDTATNT 
201 QSPTSLPSQE HVDPQATGDS ERGLSAQQQA RKAKQEEKEE EEEEEAVARE 
251 KAGPEEVPTA ASSSHFHAGY KAIQKDDGQS DSQAVDGDGK TEASEALPSE
301 GKGELEHSQQ EEDGEEAMVG TPQGLFPQGG KGRELEHKQE EEEEEEERLS 
351 REWEDKRWSR MDQLAKELTA EKRLEGEDDP DRSMKLSFRT RAYGFRDPGP 
401 QLRRGWRPSS REDSVEARSD FEEKKEEEGS ANRRAEDQEL ESLSAIEAEL
451 EKVAHQLQAL RRG                                         
Fig. 1 Localization of identified peptides within chromogranin A
sequence
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Along with the four proteins belonging to the granins
family, we identified 115 other proteins secreted by mouse
neuroblastoma cells. Proteins were identified in two runs of
identification with at least two peptides detected with the
score above the threshold value. Five main molecular func-
tion categories of proteins were found by functional catego-
rization using PANTHER system: catalytic (GO:0003824),
binding (GO:0005488), structural molecule (GO:0005198),
receptor (GO:0004872), and enzyme regulator (GO:0030
234) activities (Fig. 3).
All 119 detected proteins were verified for the presence
of the signal fragments in their sequences. Fifty-six of them
with signal sequences required for translocation into endo-
plasmic reticulum are presented in Table 2. The remaining
63 proteins without predicted signal sequence were ana-
lyzed using SecretomeP algorithm. We found out 17 pro-
teins with neural network (NN) score above 0.5, which
indicates that they could undergo nonclassical secretion
(Table 3).
Discussion
In the pool of proteins secreted by mouse neuroblastoma
cells, we identified four members of the granin family: CgA,
CgB, Sg III, and VGF. The elevated level of CgA was
previously found not only in the plasma of patients with
neuroblastoma and ganglioneuroma but also with a wide
range of tumors like pheochromocytoma; carcinoid tumors
of the gastrointestinal tract, lung, and ovary; pancreatic
endocrine tumors; and medullary thyroid carcinoma [11].
CgA may play a role in the regulation of tumor angiogen-
esis, vascular permeability, and endothelial barrier function
affecting the response to certain therapies [30]. Human
CgA-derived bioactive peptides involve vasostatin I,
beta-granin/vasostatin II, prochromacin, chromacin,
pancreastatin, catestatin, parastatin, WE-14, and serpinin
[1, 12, 19, 28, 34]. We detected five peptides located within
bioactive regions of CgA sequence: the peptide
K.ELQDLALQGAK.E was located within beta-granin/
vasostatin II region, two others (K.TEASEALPSEGK.G
and K.DDGQSDSQAVDGDGK.T) were located in
pancreastatin region, and another two polypeptides
(K.VAHQLQALR.R and R.AEDQELESLSAIEAELEK.V)
were found in serpinin region. Increased level of
pancreastatin concentrations correlates with tumor differen-
tiation, localized clinical stage, and a favorable outcome for
children with neuroblastoma. Kogner et al. suggested that
pancreastatin in plasma and tumor tissue can be used as a
marker indicating favorable tumor behavior [25]. The newly
identified CgA-derived peptide—serpinin—stimulates tran-
scription of protease nexin-1 which is an inhibitor of plas-
min protease and its increased expression stabilizes granule
proteins in the Golgi complex [26]. Inhibition of plasmin
Fig. 2 Western blot detection of granins in the supernatants of neuro-
blastoma cells. Line 1 secretogranin III, line 2 chromogranin A, line 3
chromogranin B, line 4 VGF. M molecular weight markers
Catalytic activity (GO:0003824) - 69 proteins:
1. ligase activity (GO:0016874) 4 proteins 
2. oxidoreductase activity (GO:0016491) 
21 proteins
3. transferase activity (GO:0016740) 15 proteins
4. hydrolase activity (GO:0016787) - 23 proteins 
5. RNA splicing factor activity (GO:0031202) 
7 proteins 
6. lyase activity (GO:0016829) 4 proteins
7. isomerase activity (GO:0016853) 10 proteins 
Enzyme regulator activity 
(GO:0030234) - 13 proteins
Receptor activity 
(GO:0004872) - 13 proteins 
Binding (GO:0005488) - 51 proteins:
1. nucleic acid binding (GO:0003676) -18 proteins 
2. calcium ion binding (GO:0005509) - 6 proteins 
3. calcium-dependent phospholipid binding 
(GO:0005544) - 4 proteins 
4. protein binding (GO:0005515) 35 proteins: 
- receptor binding (GO:0005102) 16 proteins 
- cytoskeletal protein binding (GO:0008092) - 4 
proteins 
- calmodulin binding (GO:0005516) 5 proteins 
Structural molecule activity (GO:0005198) 
22 proteins: 
1. structural constituent of ribosome 
(GO:0003735) 3 proteins 
2. extracellular matrix structural constituent 
(GO:0005201) 3 proteins 
3. structural constituent of cytoskeleton 
(GO:0005200) - 16 proteins 
Fig. 3 Functional classification
of proteins secreted by mouse
neuroblastoma cells using the
PANTHER analysis tool
(www.pantherdb.org)
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released during inflammatory process may also play a role
in protecting cells under adverse pathophysiological condi-
tions. Serpinin and its N-terminally modified form
pyroglutamic-serpinin (pGlu-serpinin) also prevent reactive
oxygen species and low potassium-induced cell death and
hence they may be important in neuroprotection of the
central nervous system, neurons, and pituitary cells.
Neuroprotective effect of pGlu-serpinin involves activation
of signal transduction pathway leading to upregulation of
anti-apoptotic Bcl2 proteins [31]. Therefore, serpinins may
play an important role in neuroblastoma progression
through their anti-apoptotic activities preventing host medi-
ated antitumor mechanisms.
SgIII consists of three functional regions: cholesterol-
binding domain, CgA-binding domain, and membrane
associated CPE-binding domain [20, 21]. We detected six
different peptides of SgIII (sequence coverage 18 %).
Three of them were related to CgA-binding domain
(K.EANNYEETLDKPTSR.T, K.VTPVAAVQDGFTNR.E
and K.YGTISPEEGVSYLENLDETIALQTK.N), two of
them were mapped within the cholesterol-binding domain
(R.SPPFDNQLNVEDADSTK.N and R.SPPFDNQLN
VEDADSTK.N), and one within the CPE-binding domain
(R.DFINQQADAYVEK.G). SgIII could mediate between
the core aggregate and the cholesterol-rich secretory granule
membrane, directing soluble binding cargo proteins to the
secretory granules. Proteolytic fragments derived from SgIII
have been described, however without specified biological
activity [20, 21]. Expression of SgIII in 41 of 47 investigat-
ed neuroendocrine tumors was reported [38].
Immunoreactivity of VGF has been found in most well-
differentiated neuroendocrinal tumors [39, 41]. Neuroblas-
toma cells were identified as VGF positive and the VGF
expression is upregulated during differentiation [43]. VGF
peptides are present in endocrine cells early during devel-
opment and adulthood and VGF increases in hyperplasia
and tumors [41]. Different peptide fragments have been
proposed to derive from VGF, including NAPP, NERP,
Table 2 Proteins with the signal sequence identified in the secretome of neuroblastoma cells
NCBI ID Protein name Gene NCBI ID Protein name Gene
gi|1083243 Hypoxia upregulated protein 1 Hyou1 gi|1381582 Sulfated glycoprotein 1 Psap
gi|11066226 Cathepsin Z Ctsz gi|13938049 Fibulin 1 Fbln1
gi|11596855 Transferrin receptor protein 1 Tfrc gi|14250422 Phosphogluconate dehydrogenase Pgd
gi|12746426 CTF1-alpha Clstn1 gi|1568625 Laminin subunit alpha-4 Lama4
gi|12841873 Nucleobindin-1 Nucb1 gi|192150 Clusterin alpha chain Clu
gi|12860234 Lysosomal protective prot.-cathepsin A Ctsa gi|2498391 Follistatin-related protein 1 Fstl1
gi|129729 Protein disulfide-isomerase P4hb gi|28972103 Peroxidasin homolog Pxdn
gi|1345609 Bone morphogenetic protein 1 Bmp1 gi|293691 Laminin subunit gamma-1 Lamc1
gi|17390745 Complement C1s-A, light chain C1sa gi|38372875 Fibronectin Fn1
gi|227293 Cathepsin B Ctsb gi|396821 Fibulin-1 Fbln1
gi|547841 Low-density lipoprotein receptor Ldlr gi|437125 Insulin-like growth factor-binding protein 5 Igfbp5
gi|6678359 Transketolase Tkt gi|50409 Chromogranin B (Secretogranin-1) Chgb
gi|6753556 Cathepsin D Ctsd gi|556299 Collagen alpha-2(IV) chain Col4a2
gi|6755106 Lysyl hydroxylase 1 Plod1 gi|607132 Adipocyte enhancer-binding prot. 1 Aebp1
gi|6755863 Endoplasmin Hsp90b1 gi|6677867 Secretogranin-3 Scg3
gi|7242187 Legumain Lgmn gi|6678077 SPARC Sparc
gi|9558454 Peptidase inhibitor 16 Pi16 gi|6680932 Chromogranin A precursor Chga
gi|9790019 Acid ceramidase subunit beta Asah1 gi|6755144 Galectin-3-binding protein Lgals3bp
gi|200397 Protein disulfide-isomerase A3 Pdia3 gi|7657027 Dickkopf-related protein 3 Dkk3
gi|309085 Amyloid beta App gi|86476054 VGF nerve growth factor inducible Vgf
gi|1304157 Heat shock 70 kDa protein 5 Hspa5 gi|11762010 Cystatin C precursor Cst3
gi|114775 Beta-2-microglobulin B2m gi|4959705 Fibulin 2 Fbln2
gi|47894398 Tropomyosin 4 Tpm4 gi|125490382 Procollagen C-proteinase enhancer protein Pcolce
gi|148693781 Neural cell adhesion molecule 1 Ncam1 gi|6753094 Amyloid-like protein 2 Aplp2
gi|53035 Peptidyl-prolyl cis-trans isomerase Ppib gi|20381317 Aggrecanase-1 Adamts4
gi|6679465 Glucosidase 2 subunit beta Prkcsh gi|6175081 Fractalkine Cx3cl1
gi|10947006 Fetuin-B Fetub gi|6680840 Calumenin Calu
gi|12963609 Sulfhydryl oxidase 1 Qsox1 gi|50852 Granulin-7 Grn
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TLQP, AQEE, and LQEQ [40, 52, 53]. We detected seven
peptides of VGF protein, four of them derived from previ-
ously described regions: R.LLQQGLAQVEAGR.R
(NERP-1), K.NAPPEPVPPPR.A (NAPP-129), R.HHPDLE
AQAR.R (TLQP-62/30), and R.SQEEAPGHR.R (APGH).
Remaining three polypeptides (R.SPQPPPPAPAR.D(509–519),
R.ELQETQQER.E(353–661), and K.LHLPADDVVSIIEE
VEEK.R(466–483)) are derived from regions without known
biological activity. Biological roles of VGF-derived peptides
like regulation of energy balance, food intake, body fluid
homeostasis, and reproduction were described [4, 5, 13, 23,
45, 52]. Clinical and preclinical data links VGF-derived
Table 3 The NN scores rank of identified proteins without the signal sequence (scores calculated using SecretomeP algorithm)
NCBI ID Protein name Gene NN
score




Sumo2 0.883 gi|12844989 Phosphoglycerate mutase 1 Pgam1 0.408
gi|6679108 Nucleophosmin Npm1 0.803 gi|193442 Galectin-1 Lgals1 0.402
gi|5007032 Transgelin-2 Tagln2 0.790 gi|202423 Phosphoglycerate kinase 1 Pgk1 0.400
gi|226471 Cu/Zn superoxide dismutase Sod1 0.760 gi|26324898 Eukaryotic translation elongation factor 2 Eef2 0.360
gi|1167510 Ubiquitin Ubc 0.749 gi|6671539 Fructose-bisphosphate aldolase A Aldoa 0.357
gi|55291 Vimentin Vim 0.728 gi|387496 Nucleoside diphosphate kinase A Nme1 0.349
gi|6755911 Thioredoxin Txn 0.698 gi|3219774 Peroxiredoxin-6 Prdx6 0.346
gi|42542422 Heat shock cognate 71 kDa
protein
Hspa8 0.641 gi|5803225 14-3-3 protein epsilon Ywhae 0.330
gi|13529464 Nucleolin Ncl 0.570 gi|45598372 Brain acid soluble prot. 1 Basp1 0.328
gi|6754524 L-lactate dehydrogenase A
chain
Ldha 0.568 gi|13569841 Thioredoxin reductase 1, cytoplasmic Txnrd1 0.324
gi|6755040 Profilin-1 Pfn1 0.560 gi|51452 60 kDa heat shock protein Hspd1 0.320
gi|6678437 Translationally controlled
tumor protein
Tpt1 0.527 gi|4503545 Eukaryotic transl. initiation factor 5A-1 IF5A1 0.319
gi|1517864 Phosphatidylethanolamine
binding protein
Pebp1 0.522 gi|6679078 Nucleoside diphosphate kinase B Nme2 0.307
gi|984938 Proteasome subunit beta
type-6
Psmb6 0.512 gi|3914804 Heterogeneous nuclear rnp G Rbmx 0.300
gi|192050 Aspartate aminotransferase Got2 0.510 gi|40556608 Heat shock protein 1 beta Hsp90ab1 0.296
gi|809561 Actin, cytoplasmic 2 Actg1 0.505 gi|3065929 14-3-3 protein gamma Ywhag 0.290
gi|52865 Lamin-A/C Lmna 0.505 gi|20178336 Tropomyosin alpha-3 Tpm3 0.261
gi|74178273 Actin, cytoplasmic 1 Actb 0.498 gi|2495342 Heat shock 70 kDa protein 4 Hspa4 0.261
gi|6754910 Nuclear migration protein
nudC
Nudc 0.496 gi|6756039 14-3-3 protein theta Ywhaq 0.256
gi|7106387 Proteasome subunit alpha
type-5
Psma5 0.494 gi|115496850 Spectrin alpha 2 SPTA2 0.244
gi|576133 Glutathione S-transferase
P 1
Gstp1 0.485 gi|1841387 14-3-3 protein zeta/delta Ywhaz 0.244
gi|202210 Tubulin alpha-1B chain Tuba1b 0.472 gi|556301 Elongation factor1-alpha1 Eef1a1 0.229
gi|2253159 Peripherin Prph 0.461 gi|790470 Proliferation-associated protein 2 G4 Pa2g4 0.194
gi|7106439 Tubulin, beta 5 Tubb5 0.458 gi|13384620 Heterogeneous nuclear rnp K Hnrnpk 0.177
gi|19527048 Heterogeneous nuclear
rnp F
Hnrnpf 0.450 gi|6754254 Heat shock protein HSP 90-alpha Hsp90aa1 0.174
gi|387422 Malate dehydrogenase Mdh2 0.449 gi|55217 Transitional ER ATPase Vcp 0.163
gi|115558 Neural cell adhesion
molecule L1
L1cam 0.441 gi|14389431 Stress-induced phosphoprotein 1 Stip1 0.155
gi|70794816 Alpha-enolase Eno1 0.439 gi|2144100 SET nuclear oncogene Set 0.103
gi|6679439 Peptidyl-prolyl cis-trans
isomerase A
Ppia 0.421 gi|1711240 Heterogeneous nuclear rnp A1 Hnrnpa1 0.087
gi|1405933 Pyruvate kinase isozymes
M1/M2
Pkm2 0.418 gi|3329498 Heterogeneous nuclear rnp A2/B1 Hnrnpa2b1 0.081
gi|1864018 Triosephosphate isomerase Tpi1 0.418 gi|109866 Nucleosome assembly protein 1-like 1 Nap1l1 0.042
gi|11230802 Alpha-actinin-4 Actn4 0.417
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peptides in models of human depression (TLQP 62) [49],
neuropathic and inflammatory pain (TLQP 21, AQEE 30)
[10, 42], amyotrophic lateral sclerosis, Parkinson’s, and
Alzheimer’s diseases [6, 37].
Different CgB peptides were detected in most neuroen-
docrine tumors [39]. Previously identified peptides derived
from CgB include secretolytin(614–626), chrombacin(564–626)
and fragment CgB(312–331), CgB(1–41), GAWK(420–493), CCB
(597–653), BAM1745(547–560), PE 11(555–565), Sr17(586–602),
and Hq34(603–636) [27, 48, 54]. We identified eight peptides
of CgB in the pool of proteins secreted by mouse neuro-
blastoma cells. Most of the peptides detected in our study
are localized in N-terminal part of chromogranin B sequence
and are not homologous to known bioactive peptides de-
rived from this protein. Two of them (R.DHNEEMVTR.C
and R.LLDEGHYPVR.E) were located in regions previous-
ly described as CgB(1–41) and GAWK. GAWK-like immu-
noreactivity is produced by a variety of endocrine tumors
and may serve as a plasma tumor marker, especially in
patients with pancreatic endocrine tumors [47]. Changes in
the level of CgB and derived peptides in CSFs of patients
with neurological diseases (e.g., multiple sclerosis,
frontotemporal dementia, schizophrenia) were described
(for review, [6]). Some conflicting results previously
obtained from immunohistological studies using different
antibodies may probably indicate differences in processing
of particular epitopes in the tumors. That is why using
alternative methods like mass spectrometry for investigating
of peptides resulted from proteolytic cleavage of proteins
(“degradomics”) could overcome limitations of antibody-
based methods [14].
Along with granins, we identified 115 other proteins
secreted by mouse neuroblastoma cells. We examined their
sequences for the presence of the extracellular transport
signals to determine the mode of secretion. Granins and 52
other proteins with N-terminal signal peptide included in
Table 2 can be secreted via the classical pathway (translo-
cation into endoplasmic reticulum, transport through Golgi
complex, and secretory vesicles). Remaining 63 proteins
could be transported using mechanisms of the nonclassical
pathway (import into intracellular vesicles followed by its
fusion with the plasma membrane, direct translocation
across the plasma membrane, “flip-flop”-mediated secretion
of membrane anchored proteins, or secretion in exosomes).
To verify the possibility of nonclassical protein secretion,
we applied SecretomeP algorithm [8] and we found 16 pro-
teins with NN score above 0.5 (predictions of the non signal
peptide triggered secretion, Table 3). However, NN score
below 0.5 does not exclude that proteins can be secreted
using the nonclassical pathway. So far, only limited number
of proteins have been shown experimentally as nonclassical
secretory proteins. We detected galectin and thioredoxin
which have no signal peptides and were previously
described as exported by the alternative pathway [35, 44];
however, NN score for galectin was calculated in the
SecretomeP below 0.5.
Functional categorization of detected proteins was
performed using PANTHER system (http://www.pantherdb.
org/) [36, 50]. Proteins displayed five main molecular func-
tion categories: catalytic (GO:0003824), binding (GO:0005
488), structural molecule (GO:0005198), receptor (GO:00
04872), and enzyme regulator (GO:0030234) activities
(Fig. 2). As expected for secreted proteins, a large group
was classified as possessing receptor binding or receptor
activities and catalytic or enzyme regulatory activities. We
also indentified group of proteins with structural molecule
activity (GO:0005198) belonging to the structural constitu-
ent of cytoskeleton (GO:0005200). The possible contribu-
tion of cytoskeletal proteins or their interactions seem to be
a potential area for investigating cell communication mech-
anisms involved in neuroblastoma.
Proteins secreted by mouse neuroblastoma cells can repre-
sent different aspects of cancer pathobiology. Among them,
we found proteins involved in cell cycle and proliferation
(e.g., Nap1l1, Nudc, Vcp, Tubb5, Ywhae, Ywhaq, Ywhag,
and Ywhaz), regulation of apoptosis (Clu, Set, Tpt1, Lgals1,
Hspa4, and Hspa8), and angiogenesis (L1cam, Pcolce, and
Col4A2), proteases, and proteases inhibitors (Ctsa, Ctsb, Ctsd,
Ctsz, Cst3, Adamts4, Bmp1, Pcolce, and Lgmn). We found
out also a group of proteins originated from cytoskeleton
complex (Actg1, Actb, Tpm3, Tpm4, Prph, Vim, Nudc,
Tuba1b, and Tubb5) and proteins involved in the regulation
of the cell adhesion (Ncam1, Ldlr, Fn1, L1cam, Fbln1, La-
ma4, Clstn1, and Lamc1). Proteins secreted by cancer cells
might play an important role in cancer development and
progression. Their analysis can provide insights into the me-
tastasis, angiogenesis, tumor growth, and resistance to anti-
proliferative signals.Metastatic cascade involves epithelial-to-
mesenchymal transition, extracellular matrix degradation,
intra- and extravasation, and anoikis evasion. All those steps
require specific changes on the level of intra- and extracellular
proteins (for review, [24]). Mass spectrometry-based approach
to detect and characterize proteins of cancer secretome seems
to be a valuable tool in analysis of biomarkers of oncological
and neurological disorders. This approach can also supple-
ment antibody-based methods when the protein is affected by
differences in epitope processing in cells under pathological
conditions. We detected polypeptides from four granins se-
creted by neuroblastoma cells. Many of them were homolo-
gous to previously described biologically active regions of
granins; however, for VGF and CgB, we detected peptides not
related to known bioactivities. Identification of proteins in
extracellular space, involved in cell cycle, proliferation, apo-
ptosis, angiogenesis, proteolysis, and the cell adhesion, may
help to explain mechanisms of cell communication during
neuroblastoma progression.
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